Literature DB >> 20691260

Untranslated regions of thyroid hormone receptor beta 1 mRNA are impaired in human clear cell renal cell carcinoma.

Adam Master1, Anna Wójcicka, Agnieszka Piekiełko-Witkowska, Joanna Bogusławska, Piotr Popławski, Zbigniew Tański, Veerle M Darras, Graham R Williams, Alicja Nauman.   

Abstract

Thyroid hormone receptor β1 (TRβ1) is a hormone-dependent transcription factor activated by 3,5,3'-l-triiodothyronine (T3). TRβ1 functions as a tumor suppressor and disturbances of the THRB gene are frequent findings in cancer. Translational control mediated by untranslated regions (UTRs) regulates cell proliferation, metabolism and responses to cellular stress, processes that are involved in carcinogenesis. We hypothesized that reduced TRβ1 expression in clear cell renal cell cancer (ccRCC) results from regulatory effects of TRβ1 5' and 3'UTRs on protein translation. We determined TRβ1 expression and alternative splicing of TRβ1 5' and 3'UTRs in ccRCC and control tissue together with expression of the type 1 deiodinase enzyme (coded by DIO1, a TRβ1 target gene). Tissue concentrations of T3 (which are generated in part by D1) and expression of miRNA-204 (an mRNA inhibitor for which a putative interaction site was identified in the TRβ1 3'UTR) were also determined. TRβ1 mRNA and protein levels were reduced by 70% and 91% in ccRCC and accompanied by absent D1 protein, a 58% reduction in tissue T3 concentration and 2-fold increase in miRNA-204. Structural analysis of TRβ1 UTR variants indicated that reduced TRβ1 expression may be maintained in ccRCC by posttranscriptional mechanisms involving 5'UTRs and miRNA-204. The tumor suppressor activity of TRβ1 indicates that reduced TRβ1 expression and tissue hypothyroidism in ccRCC tumors is likely to be involved in the process of carcinogenesis or in maintaining a proliferative advantage to malignant cells.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20691260     DOI: 10.1016/j.bbadis.2010.07.025

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  19 in total

Review 1.  MicroRNAs in thyroid cancer.

Authors:  Albert de la Chapelle; Krystian Jazdzewski
Journal:  J Clin Endocrinol Metab       Date:  2011-08-24       Impact factor: 5.958

Review 2.  Iodothyronine deiodinases and cancer.

Authors:  A Piekiełko-Witkowska; A Nauman
Journal:  J Endocrinol Invest       Date:  2011-05-27       Impact factor: 4.256

3.  Thyroid hormone receptor beta (THRB) is a major target gene for microRNAs deregulated in papillary thyroid carcinoma (PTC).

Authors:  Krystian Jazdzewski; Joanna Boguslawska; Jaroslaw Jendrzejewski; Sandya Liyanarachchi; Janusz Pachucki; Kazimierz A Wardyn; Alicja Nauman; Albert de la Chapelle
Journal:  J Clin Endocrinol Metab       Date:  2010-12-15       Impact factor: 5.958

4.  Disturbed expression of splicing factors in renal cancer affects alternative splicing of apoptosis regulators, oncogenes, and tumor suppressors.

Authors:  Agnieszka Piekielko-Witkowska; Hanna Wiszomirska; Anna Wojcicka; Piotr Poplawski; Joanna Boguslawska; Zbigniew Tanski; Alicja Nauman
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

5.  MiR-224 targets the 3'UTR of type 1 5'-iodothyronine deiodinase possibly contributing to tissue hypothyroidism in renal cancer.

Authors:  Joanna Boguslawska; Anna Wojcicka; Agnieszka Piekielko-Witkowska; Adam Master; Alicja Nauman
Journal:  PLoS One       Date:  2011-09-02       Impact factor: 3.240

6.  Epigenetic regulation of thyroid hormone receptor beta in renal cancer.

Authors:  Anna Wojcicka; Agnieszka Piekielko-Witkowska; Hanna Kedzierska; Beata Rybicka; Piotr Poplawski; Joanna Boguslawska; Adam Master; Alicja Nauman
Journal:  PLoS One       Date:  2014-05-21       Impact factor: 3.240

7.  A Novel Method for Gene-Specific Enhancement of Protein Translation by Targeting 5'UTRs of Selected Tumor Suppressors.

Authors:  Adam Master; Anna Wójcicka; Kamilla Giżewska; Piotr Popławski; Graham R Williams; Alicja Nauman
Journal:  PLoS One       Date:  2016-05-12       Impact factor: 3.240

8.  THRB genetic polymorphisms can predict severe myelotoxicity after definitive chemoradiotherapy in patients with esophageal squamous cell carcinoma.

Authors:  Ikuya Miki; Tsutomu Nakamura; Akiko Kuwahara; Motohiro Yamamori; Kohshi Nishiguchi; Takao Tamura; Tatsuya Okuno; Hideaki Omatsu; Shigeto Mizuno; Midori Hirai; Takeshi Azuma; Toshiyuki Sakaeda
Journal:  Int J Med Sci       Date:  2012-10-23       Impact factor: 3.738

9.  Common genetic variants in pituitary-thyroid axis genes and the risk of differentiated thyroid cancer.

Authors:  Susana Pastor; Abdelmounaim Akdi; Eddy R González; Juan Castell; Josefina Biarnés; Ricard Marcos; Antonia Velázquez
Journal:  Endocr Connect       Date:  2012-10-10       Impact factor: 3.335

10.  NotI microarrays: novel epigenetic markers for early detection and prognosis of high grade serous ovarian cancer.

Authors:  Vladimir Kashuba; Alexey A Dmitriev; George S Krasnov; Tatiana Pavlova; Ilya Ignatjev; Vasily V Gordiyuk; Anna V Gerashchenko; Eleonora A Braga; Surya P Yenamandra; Michael Lerman; Vera N Senchenko; Eugene Zabarovsky
Journal:  Int J Mol Sci       Date:  2012-10-18       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.